Company Filing History:
12 out of 1,627 
2 out of 832,761 Years Active: 1999-2017
Title: Blas Frangione: Innovator in Prion Disease Research
Introduction
Blas Frangione is a prominent inventor based in New York, NY, known for his significant contributions to the field of medical research, particularly in the area of prion diseases. With a total of 14 patents to his name, Frangione has made remarkable strides in developing innovative solutions to combat these challenging conditions.
Latest Patents
Frangione's latest patents include groundbreaking work on mucosal immunization to prevent prion infection. This patent describes vaccines against prion disease that elicit a humoral immune response when administered mucosally. The vaccines consist of a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog, along with an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin, and aluminum hydroxide. Additionally, he has developed methods for treating amyloid disease, which involve clearing amyloid peptides from bodily fluids such as blood. These methods are based on the administration of compounds capable of binding to amyloid-beta (Aβ) or through dialysis and plasma exchange to remove Aβ peptides from circulation.
Career Highlights
Frangione has had a distinguished career, working at New York University, where he has contributed to various research initiatives. His work has been pivotal in advancing our understanding of prion diseases and developing potential treatments.
Collaborations
Throughout his career, Frangione has collaborated with notable colleagues, including Thomas M. Wisniewski and Einar M. Sigurdsson. These collaborations have further enriched his research and expanded the impact of his inventions.
Conclusion
Blas Frangione's innovative work in the field of prion disease research has led to significant advancements in medical science. His patents and collaborations reflect his dedication to improving health outcomes for individuals affected by these challenging conditions.